Introduction {#s1}
============

There has been convincing evidence that alcohol ingestion is carcinogenic to humans and causally related to liver, colorectal, breast and upper aerodigestive tract (UADT) cancers [@pone.0037227-IARC1]. Although multiple mechanisms are involved in alcohol-mediated carcinogenesis, it has been shown that acetaldehyde (AA), the oxidative product of ethanol (commonly called alcohol), rather than alcohol itself is the principal carcinogenic material in alcohol metabolism [@pone.0037227-Seitz1]. AA interferes at many sites with DNA synthesis and repair and consequently has direct mutagenic and carcinogenic effects [@pone.0037227-Seitz2]. The key enzyme responsible for oxidation of ethanol to AA is alcohol dehydrogenase (ADH) [@pone.0037227-Jelski1]. Human ADH family is a well-defined system of enzymes which play important role in detoxification of alcohols and are categorized into several classes based on differences in substrate specificity, sensitivity to inhibitors, localization, electrophoretic migration and immunological properties [@pone.0037227-Holmes1]. In addition to the first-pass ethanol metabolism, ADH has shown various functions including activity towards hydroxysteroids, detoxification of endogenous and exogenous formaldehyde, retinoid transformation, etc. [@pone.0037227-Staab1], [@pone.0037227-Hoog1], [@pone.0037227-Chou1]. The differences of the activities of total ADH and ADH isoenzymes between cancer and healthy tissue have been demonstrated [@pone.0037227-Jelski1]. As production rate of AA is mainly modulated by ADH, it is rational that ADH activity variation may have effects on the level of AA in vivo and be one of the factors intensifying carcinogenesis.

There are seven genes that encode the seven known isozymes of human ADH. According to structural characteristics, the seven isozymes are categorized into five different classes, among which Class I isozymes account for most of the alcohol metabolism [@pone.0037227-Seitz3]. The three class I genes, *ADH1A*, *ADH1B*, and *ADH1C* (formerly known as *ADH1*, *ADH2* and *ADH3*) are very closely related; they encode alpha (α), beta (β) and gamma (γ) subunits, respectively [@pone.0037227-Edenberg1]. Functional variants (i.e., single nucleotide polymorphisms, SNPs) arousing wide concern exist in two of three genes encoding ADH enzymes (i.e., the *ADH1B* and *ADH1C* genes) [@pone.0037227-Seitz4]. The polymorphic sites for *ADH1B* are Arg48His in exon 3 (rs1229984) and Arg370Cys in exon 9 (rs2066702) and for *ADH1C* are Arg272Gln (rs1693482) and Ile350Val (rs698) [@pone.0037227-Edenberg1]. The *ADH1B\*1* allele is a name for the reference allele encoding β1 subunit which has arginine (Arg) at positions 48 and 370. *ADH1B\*2* (β2) refers to a variant allele defined by histidine (His) at position 48 while *ADH1B\*3* encoding β3 subunit that has cysteine (Cys) at position 370 [@pone.0037227-Edenberg1]. For polymorphisms in *ADH1C*, 272Arg and 350Ile carriers have the *ADH1C\*1* allele, whereas 272 Gln and 350 Val carriers have the *ADH1C\*2* allele [@pone.0037227-Hoog2]. It is worth noting that significant linkage disequilibrium has been detected between the *ADH1B* and *ADH1C* polymorphisms as well as the two variants in *ADH1C* [@pone.0037227-Yokoyama1], [@pone.0037227-Hashibe1]. These functional variants result in the production of enzymes with different kinetic properties [@pone.0037227-Edenberg1], [@pone.0037227-Tiemersma1] and subsequently the generation of different quantities of AA. For example, individuals with *ADH1C\*1* allele have an ethanol oxidizing capacity 2.5-times higher when compared to *ADH1C\*2* allele [@pone.0037227-Hoog2]. Thus, not only the amount of alcohol is determinant for organ injury, but also the genetic factors may modulate and determine carcinogenesis.

An increasing number of studies have investigated the association between *ADH* polymorphisms and cancer risk in human. Among them, studies of *ADH1C* Ile350Val variant accounted for more than others. Most of the *ADH1C* studies focused on head and neck cancer (HNC) development, and to a less extent on the cancers of breast, colorectum, etc. Although genotype frequency of Ile350Val polymorphism varies among different populations [@pone.0037227-Brennan1], evidences supporting the association between this genetic variant and risk of cancer have arisen from studies of different ethnic background [@pone.0037227-Soucek1], [@pone.0037227-Asakage1], [@pone.0037227-Solomon1]. Recently, Chang *et al.* conducted a meta-analysis to assess the association between *ADH1B* and *ADH1C* polymorphisms and risk of HNC [@pone.0037227-Chang1], and they found a reduced risk for HNC associated with *ADH1B\*2* and *ADH1C\*1* alleles. However, as the studies on *ADH1C* polymorphism and different cancer risk have shown contradictory and inconclusive results, a pooled analysis of all studies on *ADH1C* and cancer risk is needed.

Here, we performed a meta-analysis on 35 eligible case-control studies to estimate the overall cancer risk and *ADH1C* polymorphisms. Because polymorphisms of Arg272Gln and Ile350Val were in strong linkage disequilibrium and both of them can be used to distinguish *ADH1C\*1* and *ADH1C\*2* alleles, we focused on the most commonly studied polymorphism Ile350Val.

Materials and Methods {#s2}
=====================

Identification and Eligibility of Relevant Studies {#s2a}
--------------------------------------------------

PubMed and EMBASE were searched for all relevant reports (the last search update was July 18, 2011), using the search terms "ADH1C" or "ADH3", "polymorphism" and "cancer". The search was limited to English language papers. In addition, studies were identified by a manual search of the references of original studies. Of the articles with the overlapping data, we only selected the publication with the most extensive information. For inclusion in the meta-analysis, the identified articles had to meet the following criteria: (a) there were information on the evaluation of the *ADH1C* Ile350Val polymorphism and cancer risk, (b) used a case--control design, and (c) contained complete information about all genotype frequency. The exclusion criteria were as follows: (a) not for cancer research, (b) review articles, (c) reports without usable data and (d) duplicate publications.

Data Extraction {#s2b}
---------------

Two authors (Y Xue and M Wang) extracted data from all eligible publications independently and reached a consensus on all the items. For each study, the following characteristics were considered: the first author's last name, year of publication, country of origin, ethnicity, cancer type, source of control groups (population- or hospital-based controls) and numbers of genotyped cases and controls. Different ethnic descents were categorized as African, Asian, European, or Mixed (composed of different ethnic groups). Cancers of oral cavity, oropharynx, hypopharynx, larynx, esophagus and stomach were defined as upper aerodigestive tract (UADT) cancers [@pone.0037227-Terry1], [@pone.0037227-Nishimoto1]. For studies including subjects of different ethnic groups or cancer types, data were extracted separately for each ethnic group or cancer type whenever possible.

Statistical Analysis {#s2c}
--------------------

The strength of the association between the *ADH1C* Ile350Val polymorphisms and cancer risk was measured by odds ratios (ORs) with their 95% confidence intervals (CIs). The statistical significance of the summary OR was determined with the Z-test. We first explored the risks of the Ile/Val and Val/Val genotypes on cancer, compared with the wild-type Ile/Ile homozygote, and then evaluated the risks of Ile/Val + Val/Val versus Ile/Ile and Val/Val versus Ile/Val + Ile/Ile on cancer, assuming dominant and recessive effects of the variant Val allele, respectively. Stratified analyses were also performed by cancer types (if one cancer type contained less than three individual studies, it was classified as other cancers group), ethnicity, source of controls and sample size (subjects \>500 in both case and control groups or not).

In consideration of the possibility of heterogeneity across the studies, a statistical test for heterogeneity was performed by a χ^2^-based Q-test. A *P*-value greater than 0.10 for the Q-test indicated lack of heterogeneity among the studies, and then the fixed-effects model (the Mantel--Haenszel method) was used to calculate the summary OR estimate of each study. Otherwise, the random-effects model (DerSimonian and Laird method) was used. Sensitivity analyses were performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set to the pooled OR. The presence of publication bias indicates that non-significant or negative findings remain unpublished. We used Funnel plots and Egger's linear regression test to provide diagnosis of the potential publication bias. All statistical analyses were performed with the Stata software (version 8.2; StataCorp LP, College Station, TX, USA), using two-sided *P*-values.

Results {#s3}
=======

Characteristics of Studies {#s3a}
--------------------------

There were 35 studies retrieved on the basis of the search criteria for cancer susceptibility associated with *ADH1C* Ile350Val polymorphisms ([Fig. 1](#pone-0037227-g001){ref-type="fig"}). Totally, 19,154 cases and 26,519 controls were included in the meta-analysis. Study characteristics are summarized in [Table 1](#pone-0037227-t001){ref-type="table"}. Among the 35 case--control studies, there were 5 studies of Asians, 19 studies of Europeans and 8 studies of mixed descendents. Besides, 3 studies included more than one ethnic group [@pone.0037227-Hashibe1], [@pone.0037227-Olshan1], [@pone.0037227-Li1]. Thus, in total, 2 African groups, 5 Asian groups, 21 European groups and 10 groups of mixed descendents were recruited in our analyses. Controls were mainly matched on sex and age, of which 14 were population based [@pone.0037227-Terry1], [@pone.0037227-Li1], [@pone.0037227-Zhang1], [@pone.0037227-Yin1], [@pone.0037227-Visvanathan1], [@pone.0037227-Peters1], [@pone.0037227-Curtin1], [@pone.0037227-vanderLogt1], [@pone.0037227-Freudenheim1], [@pone.0037227-Yokoyama2], [@pone.0037227-Freudenheim2], [@pone.0037227-Terry2], [@pone.0037227-Schwartz1], [@pone.0037227-Harty1], 16 were hospital based [@pone.0037227-Soucek1], [@pone.0037227-Asakage1], [@pone.0037227-Solomon1], [@pone.0037227-Olshan1], [@pone.0037227-Garcia1], [@pone.0037227-Oze1], [@pone.0037227-MohelnikovaDuchonova1], [@pone.0037227-Zavras1], [@pone.0037227-Coutelle1], [@pone.0037227-Bouchardy1], [@pone.0037227-vanDijk1], [@pone.0037227-Coutelle2], [@pone.0037227-Kortunay1], [@pone.0037227-Wang1], [@pone.0037227-Sturgis1], [@pone.0037227-Chao1] and 5 studies was conducted on both population-based and hospital-based control group [@pone.0037227-Hashibe1], [@pone.0037227-Nishimoto1], [@pone.0037227-Brocic1], [@pone.0037227-Homann1], [@pone.0037227-McKay1]. Furthermore, 7 studies were conducted with subjects \>500 in both case and control groups [@pone.0037227-Hashibe1], [@pone.0037227-Yin1], [@pone.0037227-Peters1], [@pone.0037227-Curtin1], [@pone.0037227-Terry2], [@pone.0037227-Oze1], [@pone.0037227-McKay1]. There were 4 studies of breast cancer, 25 of UADT cancer, 3 of colorectal and 3 of other cancers. Among the 25 UADT cancer studies, Homann *et al*. investigated the *ADH1C* polymorphism and cancer risk in both UADT cancer and hepatocellular cancer groups [@pone.0037227-Homann1]. Thus, number of studies of "other cancers" was 4. Cancers were confirmed histologically or pathologically in most studies. The distribution of genotypes in the controls of all studies was consistent with Hardy--Weinberg equilibrium (HWE) except for 10 studies, 9 of which did not mention the HWE test [@pone.0037227-Li1], [@pone.0037227-Freudenheim1], [@pone.0037227-Freudenheim2], [@pone.0037227-Harty1], [@pone.0037227-Garcia1], [@pone.0037227-Coutelle1], [@pone.0037227-Coutelle2], [@pone.0037227-Chao1], [@pone.0037227-Brocic1] and in one study allele distributions were not in HWE for a part of controls [@pone.0037227-vanDijk1].

![Studies identified with criteria for inclusion and exclusion.](pone.0037227.g001){#pone-0037227-g001}
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###### Characteristics of studies included in the meta-analysis.

![](pone.0037227.t001){#pone-0037227-t001-1}

  First author     Year        Country            Ethnicity              Cancer types         Source of controls   Sample size  
  -------------- -------- ----------------- ---------------------- ------------------------- -------------------- ------------- ------
  Coutelle         1997        France              European                  UADT                     HB               39         37
  Harty            1997      Puerto Rico            Mixed                    UADT                     PB               146       146
  Freudenheim      1999          USA               European                 Breast                    PB               315       356
  Bouchardy        2000        France              European                  UADT                     HB               244       167
  Chao             2000         China               Asian                    UADT                     HB               88        434
  Olshan           2001          USA         European and African            UADT                     HB               173       194
  Sturgis          2001          USA               European                  UADT                     HB               229       575
  Schwartz         2001          USA               European                  UADT                     PB               333       541
  Dijk             2001      Netherlands           European                 Bladder                   HB               115       131
  Zavras           2002        Greece              European                  UADT                     HB               93         99
  Yokoyama         2002         Japan               Asian                    UADT                     PB               234       634
  Freudenheim      2003          USA                Mixed                    Lung                     PB               113       212
  Nishimoto        2004        Brazil               Mixed                    UADT                  Combined            141       134
  Coutelle         2004        German              European                 Breast                    HB               117       111
  Peters           2005          USA               European                  UADT                     PB               521       599
  Wang             2005          USA               European                  UADT                     HB               348       330
  Homann          2006\.       German              European         UADT and Hepatocellular        Combined            293       729
  Logt             2006      Netherlands           European               Colorectal                  PB               320       385
  Terry            2006          USA                Mixed                   Breast                    PB              1047       1101
  Terry            2007          USA                Mixed                    UADT                     PB               197       160
  Zhang            2007        Poland              European                  UADT                     PB               297       425
  Yin              2007         Japan               Asian                 Colorectal                  PB               685       777
  Visvanathan      2007          USA               European                 Breast                    PB               303       312
  Asakage          2007         Japan               Asian                    UADT                     HB               96        642
  Curtin           2007          USA                Mixed                 Colorectal                  PB               915       1969
  Solomon          2008         India               Mixed                    UADT                     HB               126       100
  Hashibe          2008    Multi-Countries    European and Mixed             UADT                  Combined           3393       4851
  Li               2008     South Africa      African and Mixed              UADT                     PB               237       268
  Oze              2009         Japan               Asian                    UADT                     HB               585       1170
  Garcia           2010        Brazil               Mixed                    UADT                     HB               207       244
  Duchonova        2010         Czech              European               Pancreatic                  HB               235       264
  Kortunay         2010        Turkey              European                  UADT                     HB               50        100
  Soucek           2010         Slav               European                  UADT                     HB               121       121
  Brocic           2011        Serbia              European                  UADT                  Combined            123       177
  Mckay            2011    Multi-Countries         European                  UADT                  Combined           6675       8024

UADT, upper aerodigestive tract; HB, hospital based; PB, population based; Combined, studies conducted on both population-based and hospital-based control group.

Quantitative Synthesis {#s3b}
----------------------

There was a wide variation of the 350 Val allele frequency among the controls across different ethnicities. The 350 Val allele frequency was the lowest in Asian populations and was the highest in European populations (0.05, 95% CI  = 0.03−0.09, vs. 0.40, 95% CI  = 0.36−0.44). In African and mixed populations, the allele frequency was 0.29 (95% CI  = −1.15−1.58) and 0.35 (95% CI  = 0.27−0.39), respectively. The difference among the four population groups was statistically significant (*P*\<0.001). In the overall analyses, we did not observe any significant associations between the *ADH1C* Ile350Val polymorphism and cancer risk in all the genetic models ([Table 2](#pone-0037227-t002){ref-type="table"}, [Fig. 2](#pone-0037227-g002){ref-type="fig"} of dominant model). Because population admixture may be a potential cause of inconsistent results [@pone.0037227-Deng1], we excluded studies with mixed populations to further evaluate the overall effect of *ADH1C* Ile350Val polymorphism and we still didn't find any significant associations (data not shown). However, in the stratified analysis by ethnicity, significant increased risks were found for African populations (homozygote comparison: OR  = 2.19, 95% CI  = 1.29−3.73, *P* ~heterogeneity~  = 0.989; dominant model: OR  = 1.79, 95% CI  = 1.18−2.71, *P* ~heterogeneity~  = 0.761; recessive model: OR  = 1.92, 95% CI  = 1.16−3.17, *P* ~heterogeneity~  = 0.981) and Asian populations (heterozygote comparison: OR  = 1.58, 95% CI  = 1.32−1.90, *P* ~heterogeneity~  = 0.375; homozygote comparison: OR  = 3.84, 95% CI  = 1.74−8.49, *P* ~heterogeneity~  = 0.160; dominant model: OR  = 1.65, 95% CI  = 1.38−1.96, *P* ~heterogeneity~  = 0.330; recessive model: OR  = 3.54, 95% CI  = 1.62−7.75, *P* ~heterogeneity~  = 0.154) ([Table 2](#pone-0037227-t002){ref-type="table"}, [Fig. 3](#pone-0037227-g003){ref-type="fig"} of dominant model ). When we performed stratified analyses by cancer type, we found individuals with the Val/Val genotypes had a 0.58-fold lower breast cancer risk compared with the Ile/Ile genotype (OR  = 0.58, 95% CI  = 0.34−1.00, *P* ~heterogeneity~  = 0.001, [Table 2](#pone-0037227-t002){ref-type="table"}) (*P*  = 0.049, data not shown). We did not observe any significant associations among UADT cancer, colorectal cancer and other cancers ([Table 2](#pone-0037227-t002){ref-type="table"}). However, cancer-specific analysis excluding studies with mixed populations indicated that a moderate increased risk of UADT cancer was associated with variant Val allele in dominant model (OR  = 1.17, 95% CI  = 1.01−1.36, *P* ~heterogeneity~ \<0.001, data not shown). Furthermore, when we conducted stratified analyses according to source of controls and sample size, no significant associations were found in any genetic models ([Table 2](#pone-0037227-t002){ref-type="table"}).

10.1371/journal.pone.0037227.t002

###### Stratification analyses of the *ADH1C* Ile350Val polymorphism on cancer.

![](pone.0037227.t002){#pone-0037227-t002-2}

  Variables                                      n[a](#nt102){ref-type="table-fn"}   Sample size (case/control)                      Ile/Val vs. Ile/Ile                      Val/Val vs. Ile/Ile           Ile/Val + Val/Val vs. Ile/Ile (dominant)            Val/Val vs. Ile/Val + Ile/Ile (recessive)                                                                                                                                    
  --------------------------------------------- ----------------------------------- ---------------------------- ----------------------------------------------------------- --------------------- ----------------------------------------------------------- ------------------------------------------- ----------------------------------------------------------- --------- ----------------------------------------------------------- ---------
  Total                                                         35                          19154/26519                               1.02 (0.92−1.14)                              \<0.001                             1.01 (0.87−1.16)                                         \<0.001                                        1.04 (0.94−1.16)                        \<0.001                       1.03 (0.93−1.15)                        \<0.001
  Cancer Type                                                                                                                                                                                                                                                                                                                                                                                                                                
  Breast                                                         4                           1782/1880                                0.78 (0.54−1.12)                               0.003                              0.58 (0.34−1.00)                                          0.001                                         0.73 (0.50−1.07)                         0.001                        0.72 (0.51−1.01)                         0.048
  UADT                                                          25                          14903/20901                               1.09 (0.95−1.24)                              \<0.001                             1.10 (0.93−1.31)                                         \<0.001                                        1.12 (0.98−1.28)                        \<0.001                       1.09 (0.96−1.24)                         0.004
  Colorectal                                                     3                           1920/3131                1.05 (0.92−1.21)[c](#nt104){ref-type="table-fn"}               0.537              1.07 (0.87−1.31)[c](#nt104){ref-type="table-fn"}                          0.504                         1.06 (0.93−1.21)[c](#nt104){ref-type="table-fn"}         0.566        1.06 (0.88−1.27)[c](#nt104){ref-type="table-fn"}         0.445
  Other                                                          4                            549/1336                                0.72 (0.44−1.17)                               0.008                              0.76 (0.42−1.39)                                          0.018                                         0.73 (0.44−1.20)                         0.003        0.93 (0.71−1.24)[c](#nt104){ref-type="table-fn"}         0.199
  Race[\*](#nt107){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                      
  African                                                        2                            204/198                 1.47 (0.89−2.44)[c](#nt104){ref-type="table-fn"}               0.867          **2.19 (1.29**−**3.73)** [c](#nt104){ref-type="table-fn"}                     0.989                     **1.79 (1.18**−**2.71)** [c](#nt104){ref-type="table-fn"}    0.761    **1.92 (1.16**−**3.17)** [c](#nt104){ref-type="table-fn"}    0.981
  Asian                                                          5                           1688/3657            **1.58 (1.32**−**1.90)** [c](#nt104){ref-type="table-fn"}          0.375          **3.84 (1.74**−**8.49)** [c](#nt104){ref-type="table-fn"}                     0.160                     **1.65 (1.38**−**1.96)** [c](#nt104){ref-type="table-fn"}    0.330    **3.54 (1.62**−**7.75)** [c](#nt104){ref-type="table-fn"}    0.154
  European                                                      21                          12964/17476                               0.93 (0.81−1.06)                              \<0.001                             0.98 (0.82−1.17)                                         \<0.001                                        0.94 (0.82−1.08)                        \<0.001                       1.03 (0.91−1.17)                         0.002
  Mixed                                                         10                           4294/5186                                1.04 (0.90−1.20)                               0.052                              1.05 (0.83−1.34)                                          0.013                                         1.05 (0.89−1.23)                         0.006       1.02 (0.90−1.150) [c](#nt104){ref-type="table-fn"}        0.110
  Source of controls                                                                                                                                                                                                                                                                                                                                                                                                                         
  PB                                                            14                           5663/7885                                1.05 (0.93−1.18)                               0.017                              0.98 (0.83−1.17)                                          0.019                                         1.05 (0.92−1.19)                         0.001        0.97 (0.88−1.08)[c](#nt104){ref-type="table-fn"}         0.116
  HB                                                            16                           2866/4719                                1.01 (0.79−1.29)                              \<0.001                             1.16 (0.79−1.69)                                         \<0.001                                        1.06 (0.82−1.37)                        \<0.001                       1.24 (0.93−1.66)                         0.002
  Combined                                                       5                          10625/13915                               0.95 (0.74−1.21)                              \<0.001                             0.89 (0.65−1.21)                                         \<0.001                                        0.93 (0.73−1.20)                        \<0.001                       0.96 (0.82−1.12)                         0.049
  Sample Size[d](#nt105){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                
  \<500                                                         28                           5333/8028                                1.00 (0.83−1.19)                              \<0.001                             1.00 (0.79−1.27)                                         \<0.001                                        1.02 (0.85−1.22)                        \<0.001                       1.05 (0.89−1.23)                         0.001
  \>500                                                          7                          13821/18491                               1.04 (0.96−1.13)                               0.094                              1.01 (0.89−1.15)                                          0.069                                         1.06 (0.97−1.16)                         0.026                        1.01 (0.89−1.14)                         0.049

: Number of studies.

*P* ^b^: The value of heterogeneity test.

: Fix-effects model was used when *P* value for heterogeneity test \>0.10; otherwise, random-effects model was used.

: Stratified according to subjects \>500 in both case and control groups or not.

Combined, studies conducted on both population-based and hospital-based control group.

The sum of sample size of each race group was less than total sample size because in Olshan's study, the sum of sample size of each race group was less than its total sample size.

![Forest plot of cancer risk associated with the *ADH1C* Ile350Val polymorphism (dominant model).\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](pone.0037227.g002){#pone-0037227-g002}

![Forest plot of cancer risk associated with the *ADH1C* Ile350Val polymorphism in African and Asian populations (dominant model).\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](pone.0037227.g003){#pone-0037227-g003}

Test for Heterogeneity {#s3c}
----------------------

There was significant heterogeneity for heterozygote comparison (Ile/Val versus Ile/Ile: *P* ~heterogeneity~ \<0.001), homozygote comparison (Val/Val versus Ile/Ile: *P* ~heterogeneity~ \<0.001), dominant model comparison (Val/Val + Ile/Val versus Ile/Ile: *P* ~heterogeneity~ \<0.001) and recessive model comparison (Val/Val versus Ile/Val + Ile/Ile: *P* ~heterogeneity~ \<0.001). Then, we assessed the source of heterogeneity for heterozygote comparison (Ile/Val versus Ile/Ile) by ethnicity, cancer type, source of controls and sample size. As a result, ethnicity (χ^2^ = 28.01, df  = 3, *P*\<0.001) and cancer type (χ^2^ = 8.39, df  = 3, *P*  = 0.039) but not source of controls (χ^2^ = 3.54, df  = 2, *P*  = 0.171) or sample size (χ^2^ = 0.52, df  = 1, *P*  = 0.470) were found to contribute to substantial heterogeneity.

Sensitivity Analyses {#s3d}
--------------------

Sensitivity analyses indicated that two independent studies by Hashibe *et al*. in 2008 and Homann *et al*. in 2006 were the main origin of heterogeneity [@pone.0037227-Hashibe1], [@pone.0037227-Homann1]. In addition, no other single study influenced the pooled OR qualitatively, as indicated by sensitivity analyses, suggesting that the results of this meta-analysis are stable.

Furthermore, when we performed cancer-specific and population-specific sensitivity analyses we found studies conducted by Terry *et al.* in 2006 [@pone.0037227-Terry2], Hashibe *et al*. in 2008 [@pone.0037227-Hashibe1], Homann *et al*. in 2006 [@pone.0037227-Homann1] and Terry *et al.* in 2007 [@pone.0037227-Terry1] were the main origin of heterogeneity in subgroup of breast cancer, UADT cancer, European population and mixed population, respectively. Moreover, no single study influenced the pooled OR in each subgroup, which indicated that results of stratified analyses were also stable.

Publication Bias {#s3e}
----------------

Begg's funnel plot and Egger's test were performed to evaluate the publication bias of literatures. As shown in [Fig. 4](#pone-0037227-g004){ref-type="fig"}, the shape of the funnel plots seemed symmetrical in the dominant model comparison. Then, the Egger's test was adopted to provide statistical evidence of funnel plot symmetry. The results still did not show any evidence of publication bias (t  = 0.42, *P*  = 0.674 for Val/Val + Ile/Val versus Ile/Ile).

![Begg's funnel plot for publication bias test (dominant model).\
Each point represents a separate study for the indicated association. Log\[or\], natural logarithm of OR. Horizontal line, mean effect size.](pone.0037227.g004){#pone-0037227-g004}

Discussion {#s4}
==========

Genetic variation in carcinogen metabolism pathway may exert influence on the risk of exposure-related cancer [@pone.0037227-Seitz3]. Based on the vital role of ADH1C in ethanol oxidation to AA, numerous studies have investigated the association of the functional *ADH1C* polymorphism with types of cancers. Several studies have observed significant association between *ADH1C\*1* allele and cancer risk [@pone.0037227-Terry1], [@pone.0037227-Li1], [@pone.0037227-Oze1], [@pone.0037227-Coutelle1], [@pone.0037227-vanDijk1]--[@pone.0037227-Kortunay1], [@pone.0037227-Chao1]--[@pone.0037227-Homann1]. It has been widely known that *ADH1C\*1* allele encode isozymes with higher catalytic activity than the one encoded by *ADH1C\*2* allele and result in more production of AA, which is a major part in ethanol-related carcinogenesis [@pone.0037227-Seitz2] and alcoholism [@pone.0037227-Chen1].

However, in view of the linkage disequilibrium between *ADH1B* and *ADH1C* and the fact that the kinetic differences among ADH1B isozymes are much more striking than those among the ADH1C isozymes [@pone.0037227-Eriksson1], some studies ascribed the association between *ADH1C* polymorphism and cancer risk to the reflects of effect of *ADH1B* polymorphism, especially in East Asian [@pone.0037227-Asakage1], [@pone.0037227-Yokoyama2]. But a matter of particular note was the significant difference of allele frequency between *ADH1B* and *ADH1C* polymorphism, that is, the minor allele frequency (MAF) for *ADH1B* was 0--0.025 in European (*ADH1B\*2* allele)and 0.223--0.261 in Asian (*ADH1B\*1* allele) populations while the MAF for *ADH1C* was 0.473--0.483 in European (*ADH1C\*2* allele) and 0.023--0.081 in Asian (*ADH1C\*2* allele) populations (data from www. ncbi. nlm. nih. gov/projects/SNP/snp_ref. cgi), which made the general attribution of *ADH1C* effect to its linkage with *ADH1B* not reasonable. In other words, as the two more-active alleles, *ADH1B\*2* and *ADH1C\*1* were linked and the frequency of *ADH1B\*2* was too low in European, the explanation of ADH1C effect was not well founded, especially in European. Furthermore, there were also some studies suggesting that the influence of *ADH1C* polymorphism on cancer risk was independent of that of *ADH1B* in both European and Asian populations [@pone.0037227-Hashibe1], [@pone.0037227-Chang1], [@pone.0037227-Chen2], [@pone.0037227-Risch1]. Thus, the detail mechanism underlying *ADH1C* polymorphism and cancer risk remains controversial and the hypothesis that the variant of *ADH1C* exert an independent influence on cancer risk by changing ethanol oxidizing capacity [@pone.0037227-Edenberg1] was better founded.

Although many studies have investigated the association between the *ADH1C* polymorphism and cancer risk, the results were inconsistent. In order to resolve this conflict, we conducted a meta-analysis of 35 case-control studies. Because data could be confounded by the differences between subgroups, we subsequently conducted stratified analysis by cancer type, ethnicity, source of controls and sample size. Moreover, as Deng *et al.* suggested in 2001 that population admixture may potentially elevate type I error rate of association studies and lead to inconsistent results [@pone.0037227-Deng1], we also conducted overall and cancer-specific analyses excluding studies with mixed populations to confirm the effect of this polymorphism and the impact of mixed populations.

Generally speaking, we did not find any association between Ile350Val polymorphism and overall cancer risk. This result indicated that individuals with the *ADH1C* genotype leading to more exposure to acetaldehyde from alcohol were not at statistically different risk of cancers. When we further performed analyses excluding mixed populations, there were still no associations between this polymorphism and overall cancer risk. To a certain extent, analyses excluding mixed populations confirmed the negative result of initial overall analyses.

In the analysis stratified by cancer type, we still did not find any significant associations among studies of breast cancer, UADT cancer, colorectal cancer and other cancers in any genetic model. However, a similar meta-analysis reported recently had shown that *ADH1C\*1* allele was associated with a significantly decreased risk of pharynx cancer in dominant model [@pone.0037227-Chang1]. Probably the discrepancy arose because they collect data of either Arg272Gln or Ile350Val polymorphism which were in perfect linkage disequilibrium but may have minor differences of genotype distribution [@pone.0037227-Hashibe1], [@pone.0037227-Zhang1], [@pone.0037227-Visvanathan1] and relatively small number of studies (22 studies) they included. Interestingly, we found the effect of variant 350 Val allele on breast and other cancer risk was contrary to that on UADT and colorectal cancer, although all the effects were not significant. As heterogeneity among different cancers may interfere the authenticity of result in "other cancers", the inverse result of breast cancer studies called more attention. A possible explanation is that carcinogenesis involved in different cancers is extremely diverse. Thus, specific role of ADH1C in carcinogenic mechanisms of breast cancer [@pone.0037227-Visvanathan1], [@pone.0037227-Jelski2] as well as interaction between special risk factors of breast cancer [@pone.0037227-Iwasaki1] and *ADH1C* gene may contribute to the inconsistent results.

Furthermore, when we performed cancer-specific analyses excluding studies with mixed populations, major results were nearly the same except that a moderate increased UADT cancer risk was founded in individuals carrying Val allele (i.e. dominant model). However, as the lower limit of the 95% CI was 1.01 in that comparison and the removing of some studies with relatively large sample size (although they were with mixed populations) may also decrease the reliability of result, we didn't think this result was sufficient to support the risk effect of Val allele in UADT cancer. Therefore, studies with more samples randomly selected from one homogeneous population are needed to further determine the association between this variant and specific cancer risk.

Subsequently, we found an increased risk of cancer in variant homozygote (Val/Val) carriers among Africans and in variant allele (350 Val) carriers among Asians. Studies have indicated that 350 Val allele increases the risk for alcoholism [@pone.0037227-Thomasson1], which may lead to accumulated exposure to the highly toxic and carcinogenic material, AA [@pone.0037227-Jelski1]. Thus, it is plausible that the presence of 350 Val allele puts one at a greater cancer risk through susceptibility to alcoholism. Although a few studies of Europeans suggested this variation might be significantly associated with risk of cancer [@pone.0037227-Terry1], [@pone.0037227-Coutelle1], [@pone.0037227-vanDijk1], [@pone.0037227-Coutelle2], [@pone.0037227-Kortunay1], [@pone.0037227-Brocic1], [@pone.0037227-Homann1], the overall difference was not significant. We presume that the difference among ethnic groups might be a reflection of different genetic backgrounds and environmental context. As a number of studies attributed the effect of *ADH1C* variant in East Asian to its linkage disequilibrium with *ADH1B*, it would be better for us to adjust the association found in Asian for *ADH1B* polymorphism. However, among the five studies conducted in Asian populations, only one [@pone.0037227-Asakage1] provided detailed data of *ADH1C* genotype adjusted for *ADH1B* genotype. Thus, the independent effect of *ADH1C* polymorphism in Asians could not be directly estimated in the present analysis, which to some extent was a flaw. In addition, other factors such as relatively small sample size (204 VS. 198 of African studies and 1688 VS. 3657 of Asian studies), selection bias and different matching criteria may also be a possible explanation to this result.

Although hospital-based studies may have inherent selection biases, we did not find any positive result in the stratified analysis by population-based and hospital-based controls, indicating that the different source of controls did not influence the association. In addition, because studies with small sample size may have insufficient statistical power or may have generated a fluctuated risk estimate, we performed stratified analyses according to subjects more than 500 in both case and control groups or not and no significant association was detected. These results suggested that there was no substantial impact of study sample size on this meta-analysis.

Because identification of the source of heterogeneity was very important in a meta-analysis, we subsequently detected source of heterogeneity by stratifying studies according to ethnicity, cancer type, source of control and sample size. Results showed the sources of heterogeneity were from ethnicity and cancer type, suggesting that certain effects of genetic variant were population and cancer specific.

Our meta-analysis had some advantages. First, substantial number of cases and controls were pooled from different studies, which significantly increased statistical power of the analysis. Second, studies included in our present meta-analysis strictly met our selection criteria. Third, we did not detect any publication bias indicating that the whole pooled result may be unbiased.

Except for the lacking of evaluation of independent effect of *ADH1C* adjusted for *ADH1B* in Asian, we also had a limitation of the present study. It has been identified that after generated from oxidization of alcohol by ADH enzymes, AA was further oxidized to acetate by aldehyde dehydrogenase (ALDH) enzymes and ALDH2 contributed most to the process [@pone.0037227-DruesnePecollo1]. Thus, besides ADH, activity of ALDH2 can also exert impact on accumulation of AA. A functional polymorphism in *ALDH2* has been identified (rs671) to be associated with cancer risk [@pone.0037227-Yang1], [@pone.0037227-Chen3], which lead to different activity of ALDH2 enzyme and is prevalent in Asians [@pone.0037227-DruesnePecollo1]. Although polymorphisms of *ALDH2* were not in linkage disequilibrium with *ADH*, it might influence the effect of polymorphisms of *ADH1C* through its impact on AA elimination. Therefore, *ALDH2* polymorphism was a potential confounder of the present study, especially of Asian studies. Independent and combined effect of *ADH1B*, *ADH1C* and *ALDH2* variants should be evaluated in further meta-analyses.

In conclusion, our results suggested that the *ADH1C* Ile350Val polymorphism is not a candidate for susceptibility to overall cancers. However, an increased cancer risk was observed in populations among African and Asian, but not in European and mixed race, which may be a reflection of ethnic differences. Additional larger studies assessing gene-gene and gene-environment interactions should be performed to further clarify the association of *ADH* genetic variants and cancer risk.
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